Skip to content

Assessment of Factors That Affected Respiratory Parameters in Mucopolysaccharidoses Patients

Assessment of Factors That Affected Respiratory Parameters in Mucopolysaccharidoses Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04491747
Enrollment
24
Registered
2020-07-29
Start date
2019-02-01
Completion date
2020-02-01
Last updated
2020-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucopolysaccharidoses

Keywords

Respiratory muscles, exercise test

Brief summary

Respiratory system affects in mucopolysaccharidosis (MPS) disease. Respiratory system symptoms are seen in almost every MPS patients and respiratory failure is one of the most common causes of death in this population. The aim of the study was to evaluate respiratory muscle strength and endurance, cough effectiveness and functional capacity in MPS patients and to defined the factors that affected the respiratory problem in this.

Detailed description

This study was participated MPS patients. Patients' pulmonary function test, functional capacity, respiratory muscle strength and endurance, peak cough flow was assessed and recorded. Pulmonary function test was assessed with spirometry, functional capacity was evaluated with 3-minute step test and six minute walk test (MWT). Respiratory muscle strength was evaluated mouth pressure measurement (MIP- maximal inspiratory pressure and MEP- maximal expiratory pressure) and Sniff nasal inspiratory pressure (SNIP). Respiratory muscle endurance was assessed Powerbreathe. And cough effectiveness was evaluated peak cough flow.

Interventions

DIAGNOSTIC_TESTfunctional capacity

Six minute walk test used assessment of functional capacity.

Sponsors

Hacettepe University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
7 Years to 30 Years

Inclusion criteria

* People who diagnosed Mucopolysaccharidoses disease in Hacettepe University. * Cooperation

Exclusion criteria

* Patients who were not walking ability.

Design outcomes

Primary

MeasureTime frameDescription
functional capacity15 minutesSix minute walk test: Distance walked in six minute was recorded
3 minute step test5 minutesnumber of completed step in 3 minute was recorded
Respiratory muscle strength assessment15 minutesRespiratory muscle strength was evaluated by measuring maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) and sniff nasal inspiratory pressure(SNIP). Also dynamic inspiratory muscle strength was evaluated Powerbreathe K5 device.
Respiratory muscle endurance10 minutesPressure time unit: A constant load test was used to evaluate respiratory muscle endurance. Using a PowerBreathe device (HaB International Ltd., Southam, UK), the participants were asked to breathe maintaining a constant threshold (60% of MIP) until task failure, and the test duration was recorded. Results were obtained by multiplying the set pressure by the test duration
Pulmonary functions15 minutesFVC (Forced vital capacity) assessment via spirometry
MVV (Maximal ventilatory assesssment)5 minutesMaximize ventilation by inhaling and exhaling as quickly and deeply as possible for 15 s via spirometry
cough effectiveness5 minutescough effectiveness assessment was evaluated peak cough flow meter.

Secondary

MeasureTime frameDescription
heart rate6 minutesdifference pre and post test heart beat number
oxygen saturation6 minutesdifference pre and post test percentage of oxygen saturation

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026